The use of specific inhibitory drugs of intracellular signaling pathways (such as Bruton-Kinase inhibitors) for the treatment of Waldenström's macroglobulinemia (WM) is a recognized risk factor for Aspergillus spp. infections. The overlapping clinical manifestations of the two diseases may require the involvement of different medical specialties.